Indivior (NASDAQ:INDV) Sees Strong Trading Volume

Indivior PLC (NASDAQ:INDV) shares saw strong trading volume on Thursday . 142,409 shares were traded during mid-day trading, an increase of 20% from the previous session’s volume of 118,529 shares.The stock last traded at $17.19 and had previously closed at $18.81.

Analyst Upgrades and Downgrades

Separately, Craig Hallum assumed coverage on shares of Indivior in a research report on Wednesday, April 3rd. They set a “buy” rating and a $37.00 price target for the company.

Indivior Trading Down 8.3 %

The company has a market capitalization of $2.38 billion, a price-to-earnings ratio of -867.07 and a beta of 0.46. The stock’s fifty day simple moving average is $20.50 and its 200-day simple moving average is $18.35.

Indivior (NASDAQ:INDV) last announced its quarterly earnings data on Thursday, February 22nd. The company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.15. The business had revenue of $293.00 million for the quarter, compared to analyst estimates of $260.00 million. Indivior had a net margin of 0.18% and a return on equity of 538.18%. On average, analysts anticipate that Indivior PLC will post 2.03 EPS for the current fiscal year.

Institutional Trading of Indivior

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Scopia Capital Management LP acquired a new position in Indivior during the third quarter worth about $191,743,000. Vanguard Group Inc. grew its holdings in Indivior by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 5,899,190 shares of the company’s stock valued at $90,081,000 after purchasing an additional 52,836 shares during the period. FMR LLC grew its holdings in Indivior by 53.5% in the third quarter. FMR LLC now owns 5,498,087 shares of the company’s stock valued at $119,339,000 after purchasing an additional 1,915,980 shares during the period. Norges Bank purchased a new stake in Indivior in the fourth quarter valued at approximately $36,011,000. Finally, Liontrust Investment Partners LLP purchased a new stake in Indivior in the third quarter valued at approximately $43,340,000. Institutional investors and hedge funds own 60.33% of the company’s stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.